Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies
SARS-CoV-2 항체에 대한 두 가지 다른 ADE(항체 의존적 강화) 위험
Immunology
[키워드] acute respiratory distress
acute respiratory syndrome
ADE
age
animal models
antibodies
antibody
antibody dependent enhancement
ARDS
Asymptomatic
B-cell
Betacoronavirus
caused
cellular tropism
chemokines
children
chronic disease
Convalescent plasma therapy
coronavirus
COVID-19
COVID-19 disease
COVID-19 infection
Critical
cross-reactive antibodies
Cytokine storms
dendritic cells
development
disease
disease severity
elevated
enhancement
expand
Fc receptor
immature
immune dysregulation
implication
include
Infant
infecting
Inflammatory
initial
involved
Lungs
lymphopenia
Macrophage
mast cell
Mast cells
mechanism
MERS-CoV
Middle East
mild flu-like symptoms
MIS-C
moderate
Multiple
Multisystem inflammatory syndrome
neutrophil
observation
patients
phagocytic cell
Population
Pregnancy
progression
Proinflammatory cytokine
receptor
respiratory
response
risk
Safe
SARS-CoV-1
SARS-CoV-2
SARS-CoV-2 antibody
severity of symptom
Stage
subset
syndrome
T cell
therapy
Vaccine
Vaccines
Variability
virus
with COVID-19
[DOI] 10.3389/fimmu.2021.640093 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2021.640093 PMC 바로가기 [Article Type] Immunology